CN115350276A - 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 - Google Patents

用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 Download PDF

Info

Publication number
CN115350276A
CN115350276A CN202210926503.6A CN202210926503A CN115350276A CN 115350276 A CN115350276 A CN 115350276A CN 202210926503 A CN202210926503 A CN 202210926503A CN 115350276 A CN115350276 A CN 115350276A
Authority
CN
China
Prior art keywords
dose
agent
hu5f9
priming
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210926503.6A
Other languages
English (en)
Chinese (zh)
Inventor
欧文·L·唔斯曼
马克·P·超
拉温德拉·玛吉特
刘劼
延斯-皮特·福尔克默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN115350276A publication Critical patent/CN115350276A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202210926503.6A 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 Pending CN115350276A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US62/323,330 2016-04-15
US201662427679P 2016-11-29 2016-11-29
US62/427,679 2016-11-29
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
CN201780029157.9A CN109152837A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780029157.9A Division CN109152837A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Publications (1)

Publication Number Publication Date
CN115350276A true CN115350276A (zh) 2022-11-18

Family

ID=60042716

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210926503.6A Pending CN115350276A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN201780029157.9A Pending CN109152837A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN202311544173.5A Pending CN117695387A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201780029157.9A Pending CN109152837A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
CN202311544173.5A Pending CN117695387A (zh) 2016-04-15 2017-04-14 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法

Country Status (12)

Country Link
US (3) US11472878B2 (enExample)
EP (3) EP3442578B1 (enExample)
JP (3) JP7532009B2 (enExample)
KR (3) KR20230035435A (enExample)
CN (3) CN115350276A (enExample)
AU (2) AU2017250809B2 (enExample)
CA (1) CA3019676A1 (enExample)
ES (1) ES2909835T3 (enExample)
PL (1) PL3442578T3 (enExample)
PT (1) PT3442578T (enExample)
SI (1) SI3442578T1 (enExample)
WO (1) WO2017181033A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
KR102776457B1 (ko) 2017-10-18 2025-03-06 포티 세븐, 엘엘씨 항-cd47 작용제-기초된 난소암 요법
ES2927305T3 (es) 2018-02-12 2022-11-04 Forty Seven Inc Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
EP3817769A4 (en) * 2018-07-05 2022-03-30 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
CR20210272A (es) 2018-11-26 2021-07-14 Forty Seven Inc Anticuerpos humanizados contra c-kit
AU2019390394C1 (en) 2018-11-28 2024-11-28 Forty Seven, LLC Genetically modified HSPCs resistant to ablation regime
US12441807B2 (en) 2019-09-18 2025-10-14 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
PE20230160A1 (es) 2019-12-17 2023-02-01 Pfizer Anticuerpos especificos para cd47, pd-l1 y sus usos
NZ792999A (en) * 2020-04-06 2025-08-29 Univ Leland Stanford Junior Antibody formulation
CA3194577A1 (en) * 2020-10-09 2022-04-14 Sonja SCHREPFER Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent
WO2022140659A2 (en) 2020-12-23 2022-06-30 D-10 Therapeutics, Inc. Anti-cd47 antibodies and uses thereof
JP2024503822A (ja) * 2021-01-05 2024-01-29 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189556A (zh) * 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
MX2010008696A (es) * 2008-02-07 2010-08-30 Amgen Inc Composiciones de proteina estabilizadas.
HRP20170254T1 (hr) 2010-05-14 2017-04-21 The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
EP3578569A1 (en) 2012-02-06 2019-12-11 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
KR102276974B1 (ko) 2013-02-06 2021-07-13 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
EP3495814A3 (en) 2013-03-27 2019-07-17 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2014179132A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
EP3052119B1 (en) 2013-10-01 2018-08-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
ES2728668T3 (es) 2014-01-08 2019-10-28 Univ Leland Stanford Junior Terapia dirigida para el cáncer de pulmón de células pequeñas
US10626179B2 (en) * 2014-06-08 2020-04-21 Remd Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
CA2964173A1 (en) * 2014-10-10 2016-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting cd47
NZ792999A (en) * 2020-04-06 2025-08-29 Univ Leland Stanford Junior Antibody formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189556A (zh) * 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIE LIU等: "Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential", 《PLOS ONE》, vol. 10, no. 9, 21 September 2015 (2015-09-21), pages 0137345, XP055223677, DOI: 10.1371/journal.pone.0137345 *

Also Published As

Publication number Publication date
AU2024203396A1 (en) 2024-06-06
EP3442578A1 (en) 2019-02-20
PL3442578T3 (pl) 2022-06-20
JP7532009B2 (ja) 2024-08-13
KR20240016445A (ko) 2024-02-06
CA3019676A1 (en) 2017-10-19
US11718670B2 (en) 2023-08-08
KR20180134367A (ko) 2018-12-18
SI3442578T1 (sl) 2022-05-31
EP4349412A3 (en) 2024-06-12
JP7442591B2 (ja) 2024-03-04
AU2017250809A1 (en) 2018-10-25
EP4349412A2 (en) 2024-04-10
PT3442578T (pt) 2022-05-19
KR102505253B1 (ko) 2023-03-02
CN117695387A (zh) 2024-03-15
US20190106491A1 (en) 2019-04-11
US11472878B2 (en) 2022-10-18
KR20230035435A (ko) 2023-03-13
JP2022172278A (ja) 2022-11-15
JP2024059764A (ja) 2024-05-01
AU2017250809B2 (en) 2024-02-29
JP2019515899A (ja) 2019-06-13
WO2017181033A1 (en) 2017-10-19
EP3442578A4 (en) 2019-04-10
ES2909835T3 (es) 2022-05-10
US20230406923A1 (en) 2023-12-21
CN109152837A (zh) 2019-01-04
EP4074339A1 (en) 2022-10-19
EP3442578B1 (en) 2022-02-09
US20230068235A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US11718670B2 (en) Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
US20240218077A1 (en) Anti-cd47 agent-based treatment of cd20-positive cancer
US10301387B2 (en) Methods for achieving therapeutically effective doses of anti-CD47 agents
CA2935774C (en) Targeted therapy for small cell lung cancer
JP7308191B2 (ja) 抗ｃｄ４７剤ベースの卵巣癌療法
HK40080891A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40107887A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40082292A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40029258A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082292

Country of ref document: HK